UK MHRA Guidance: Early Access to Medicines Scheme
- Sharan Murugan
- Mar 7
- 3 min read
The Early Access to Medicines Scheme (EAMS) is a regulatory initiative in the United Kingdom designed to provide patients with life-threatening or seriously debilitating conditions earlier access to promising medicines before full marketing authorisation is granted. The scheme is administered by the Medicines and Healthcare products Regulatory Agency (MHRA) and aims to accelerate patient access to innovative treatments where there is a clear unmet medical need.
The main objective of the Early Access to Medicines Scheme is to make promising new medicines available to patients as early as possible while the medicine is still undergoing regulatory evaluation.
The scheme also aims to:
Support earlier patient access to innovative treatments
Encourage development of medicines addressing unmet medical needs
Provide structured scientific evaluation before widespread clinical use
Enable healthcare professionals and patients to benefit from new therapies prior to marketing authorisation
By balancing innovation with regulatory oversight, the scheme strengthens the UK’s commitment to improving patient outcomes.
Key Components of the EAMS Process
The Early Access to Medicines Scheme involves two key stages that enable the regulatory authority to assess the medicine before it becomes available to patients.
Promising Innovative Medicine (PIM) Designation
The first step in the EAMS process is obtaining a Promising Innovative Medicine (PIM) designation. This designation indicates that a medicine has the potential to address an unmet medical need and may be eligible for the EAMS pathway.
The designation is based on preliminary clinical evidence suggesting that the medicine may offer significant benefits over existing therapies.However, a PIM designation does not allow the medicine to be supplied to patients. Instead, it confirms that the medicine is a suitable candidate for further evaluation within the EAMS framework.
Scientific Opinion
The second stage involves the MHRA issuing a Scientific Opinion. This assessment evaluates the benefit–risk profile of the medicine based on available clinical data.
If the Scientific Opinion is positive, the medicine may be supplied to patients before receiving full marketing authorisation. The opinion provides guidance to healthcare professionals on how the medicine should be used, including patient eligibility criteria and safety considerations.
The Scientific Opinion also includes detailed treatment protocols and prescribing information to ensure appropriate clinical use.
Role of Healthcare Professionals and Patients
Healthcare professionals play an important role in implementing the Early Access to Medicines Scheme.
Physicians must carefully evaluate whether the medicine is suitable for a particular patient and ensure that the patient understands the potential benefits and risks associated with treatment.
Patients receiving medicines under the EAMS pathway must also provide informed consent, as the medicine has not yet received full regulatory approval.
This collaborative approach ensures that early access occurs in a controlled and transparent clinical environment.
Responsibilities of Pharmaceutical Companies
Companies participating in the EAMS programme must meet several responsibilities during the early access phase. These responsibilities include providing sufficient evidence supporting the medicine’s potential benefits and ensuring that safety information is continuously monitored.
Companies must also ensure appropriate manufacturing standards and provide detailed information to healthcare professionals regarding the medicine’s use.
Participation in the scheme does not guarantee that the medicine will ultimately receive marketing authorisation, as full regulatory evaluation continues during development.
Benefits of the Early Access to Medicines Scheme
The Early Access to Medicines Scheme provides several advantages for both patients and the healthcare system.
For patients, it enables earlier access to potentially life-saving treatments that would otherwise remain unavailable until completion of the full regulatory approval process.
For healthcare systems and regulators, the scheme supports real-world clinical experience with innovative medicines while maintaining strict regulatory oversight.
For pharmaceutical developers, EAMS provides an opportunity to demonstrate the clinical value of their medicines in real-world settings while progressing toward full authorisation.
Regulatory Considerations and Safety Monitoring
Although medicines supplied under EAMS have not yet received full approval, regulatory oversight remains robust. Continuous monitoring of safety and clinical outcomes is essential during the early access period.
Healthcare professionals are encouraged to report adverse reactions and monitor patient outcomes carefully.
These data contribute to the broader evaluation of the medicine as it progresses toward marketing authorisation. This structured monitoring ensures that patient safety remains the highest priority throughout the early access process.
References:
For more details on this guidance, please refer to the official MHRA publications through the links provided below.
Comments